Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Genetics Extends Deal with Tokyo s Oriental Yeast

NEW YORK, July 10 – Lexicon Genetics said Tuesday it had extended and expanded a marketing collaboration with Oriental Yeast of Tokyo. 

Under the terms of the deal, Oriental Yeast will help Lexicon Genetics of The Woodlands, Texas, to promote its LexVision Database of in vivo mammalian gene function to Japanese pharmaceutical companies. Oriental Yeast will also help to market Lexicon's drug target validation technologies in the Japanese market.

Financial terms of the agreement are not disclosed. 

"The expansion of our contract with [Oriental Yeast] strengthens and confirms Lexicon's commitment to provide in vivo mammalian functional genomics and target validation to the Japanese drug discovery market," Randall Riggs, Lexicon's senior vice president of business development, said in a statement.

During the past year, Lexicon has worked with Oriental Yeast to develop a Japanese-language based website that allows researchers to access Lexicon's OmniBank library, which contains over 150,000 gene knockout clones, or more than 40 percent of all genes in the mammalian genome. 

Oriental Yeast has been involved in the biotech industry since 1968. Four years ago, the company established the Nagahama Institute for Biochemical Sciences, a research center dedicated to researching and developing new compounds. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more